Justin Chakma

Justin Chakma is the chief business officer of ARS Pharmaceuticals, Inc. He brings a strong track record of leading strategic transactions and financing efforts in the biotechnology industry.

Justin was previously VP, Head of Business Development and Strategy at Vedanta Biosciences, a clinical-stage biotech developing medicines to modulate immune responses including for allergic disease. Before that, he was a Senior Director of Business Development at Celgene (acquired by BMS) focused on immunology and neuroscience.

Prior to joining Celgene, Justin held various roles in business development, financing and venture capital at Receptos (acquired by Celgene), Auspex (acquired by Teva), and Thomas, McNerney & Partners.

Justin holds an MBA from the Wharton School of the University of Pennsylvania, and a Hon. B.A. in neuroscience and economics from the University of Toronto.